NLRP3 and Parkinson disease: Therapeutic strategies that suppress microglial activation, such as NLRP3 inflammasome inhibitors, glucagon-like peptide-1 receptor agonists, myeloperoxidase inhibitors, and C–C chemokine receptor type 3 antagonists, have demonstrated efficacy in preclinical PD models (Table 1) [115, 116].